UMCC 9955 Trastuzumab & Combo Chemotherapy Treating Urinary Tract Cancer - No Study Results Posted

UMCC 9955 Trastuzumab & Combo Chemotherapy Treating Urinary Tract Cancer (IRB 2000-0407)

This study has been completed.

Study NCT00005831 Information provided by University of Michigan Cancer Center

First Received: June 2, 2000 Last Updated: September 20, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	November 2007
Primary Completion Date:	August 2004 (Final data collection date for primary outcome measure)

Publications:

Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC; National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007 Jun 1;25(16):2218-24.

Hussain M, Petrylak D, Dunn R, et al.: Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2- positive urothelial carcinoma: results of a multi-center phase II NCI trial. [Abstract] J Clin Oncol 23 (Suppl 16): A-4507, 379s, 2005.